Denmark reassesses rejection of Novartis cancer combination to include more exceptions
The Danish Medicines Council has re-evaluated a combination treatment application from Novartis that it rejected in 2018. The answer is still no, but there are now more exceptions attached.
.jpg)
by albert rønning-andersson, translated by daniel pedersen
Members of the Danish Medicines Council have said no to an application from Novartis, which was hoping to see drugs Tafinlar (dabrafenib) and Mekinist (trametinib) approved as a as standard combination treatment for stage III melanoma with the BRAF V600 mutation, the council reports on its website.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Danish Medicines Council rejects Novartis breast cancer drug
For subscribers
